Search company, investor...
Unlearn company logo


Founded Year



Series B - II | Alive

Total Raised




Last Raised

$15M | 2 mos ago

About Unlearn

Unlearn builds machine-learning platforms to create biological digital twins for the healthcare and pharmaceutical industries. It develops generative machine learning methods to predict individual health outcomes and accelerate clinical innovation. It works with biopharma companies and regulators to ensure its methods meet scientific and regulatory standards. It was founded in 2017 and is based in San Fransisco, California.

Headquarters Location

75 Hawthorne Street Suite 560

San Francisco, California, 94105,

United States


Unlearn's Product Videos

ESPs containing Unlearn

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

Healthcare & Life Sciences / Drug R&D Tech

The digital twins & biosimulation market is a rapidly growing field that focuses on utilizing computer models to simulate biological processes and predict the behavior of drugs, devices, and other healthcare products. This market offers a range of solutions that enable the creation of "digital twins" - virtual replicas of biological systems that can be used to test the safety and efficacy of new t…

Unlearn named as Highflier among 15 other companies, including Healx, Aitia, and Syntegra.

Compete with Unlearn?

Ensure that your company and products are accurately represented on our platform.

Unlearn's Products & Differentiators

    Digital Twins

    Digital Twins, or predicted outcomes generated from AI-based disease progression models, can be incorporated into clinical trials using PROCOVA* (Prognostic Covariate Adjustment) to increase power, decrease the number of patients receiving placebo, and reduce variability. *Please note that PROCOVA is not a separate product, but the statistical approach used to incorporate Digital Twins in clinical trials.

Expert Collections containing Unlearn

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Unlearn is included in 11 Expert Collections, including Clinical Trials Tech.


Clinical Trials Tech

341 items

Companies developing products and services to streamline drug R&D, from drug discovery, pre-clinical testing, and clinical trials.


Artificial Intelligence

10,627 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.


Biopharma Tech

5,567 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.


Conference Exhibitors

5,302 items


Digital Health 150

300 items

The winners of the second annual CB Insights Digital Health 150.


Digital Health

10,338 items

The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.

Unlearn Patents

Unlearn has filed 8 patents.

The 3 most popular patent topics include:

  • Machine learning
  • Artificial neural networks
  • Design of experiments
patents chart

Application Date

Grant Date


Related Topics




Artificial neural networks, Machine learning, Classification algorithms, Experimental cancer drugs, Continuous distributions


Application Date


Grant Date



Related Topics

Artificial neural networks, Machine learning, Classification algorithms, Experimental cancer drugs, Continuous distributions



Latest Unlearn News

Biotech AI startup Unlearn adds $15 million and OpenAI CTO to board

Mar 21, 2023

By Krystal Hu (Reuters) – Unlearn.AI, which has built a machine learning platform that creates “digital twin” profiles of patients in clinical trials, has raised $15 million to expand partnerships and accelerate regulatory approval, the company told Reuters on Tuesday. The investment from Radical Ventures and Wittington Ventures valued the startup at $265 million, the company said. Mira Murati, chief technology officer at Microsoft-backed OpenAI, is joining the startup’s board. “The team at Unlearn is working on applications of AI that have incredible potential to revolutionise healthcare, diagnostics and treatment,” Murati told Reuters. While generative AI is known for creating content like text, images, and even computer code, Unlearn uses it to build digital twins to speed up clinical drug trials through its neural networks. If successful, Unlearn’s software could lower costs for drug developers by cutting the number of enrollments needed for clinical trials by replacing patients who receive a placebo. The funding Unlearn raised came after it won approval from the European Medicines Agency (EMA) in September for using its AI-driven approach for conducting smaller and quicker clinical trials and struck several multi-million dollar deals with pharmaceutical companies, including Merck. San Francisco-based Unlearn focuses on a relatively novel application of generative AI. The technology, where AI learns how to take actions from past data, has become widely known through applications including OpenAI’s viral chatbot ChatGPT. By collecting patient data from research studies, Unlearn’s platform computes a twin for each patient in a clinical trial and populates the control arm of the research with these twins. With a focus on Phase III clinical trials, Charles Fisher, chief executive at Unlearn said gaining approvals from regulators including the U.S. Food and Drug Administration is critical to commercializing the technology to global drugmakers. “For us the big priority on the regulatory front is to partner with drugmakers to run trials and set a precedent,” said Fisher. Unlearn has raised a total $85 million from investors including Insight Partners, 8VC, and Mubadala Ventures. (Reporting by Krystal Hu in New York; Editing by Sonali Paul) Disclaimer: This report is auto generated from the Reuters news service. ThePrint holds no responsibilty for its content. Subscribe to our channels on YouTube & Telegram Support Our Journalism India needs fair, non-hyphenated and questioning journalism, packed with on-ground reporting. ThePrint – with exceptional reporters, columnists and editors – is doing just that. Sustaining this needs support from wonderful readers like you. Whether you live in India or overseas, you can take a paid subscription by clicking here .

Unlearn Frequently Asked Questions (FAQ)

  • When was Unlearn founded?

    Unlearn was founded in 2017.

  • Where is Unlearn's headquarters?

    Unlearn's headquarters is located at 75 Hawthorne Street, San Francisco.

  • What is Unlearn's latest funding round?

    Unlearn's latest funding round is Series B - II.

  • How much did Unlearn raise?

    Unlearn raised a total of $80M.

  • Who are the investors of Unlearn?

    Investors of Unlearn include Radical Ventures, Wittington Ventures, DCVC, 8VC, Mubadala Investment Company and 6 more.

  • Who are Unlearn's competitors?

    Competitors of Unlearn include Perceiv AI and 8 more.

  • What products does Unlearn offer?

    Unlearn's products include Digital Twins and 1 more.

Compare Unlearn to Competitors

My Intelligent Machines Logo
My Intelligent Machines

My Intelligent Machines develops a platform as a service to help biologists analyze genomic data using artificial intelligence (AI). The platform finds the appropriate algorithms to analyze the user's data and generates text on its methods of analysis. It was founded in 2016 and is based in Montreal, Canada.

Owkin Logo

Owkin specializes in artificial intelligence technologies applied to clinical research and developing drugs and treatments for patients. It empowers researchers in hospitals, universities, and the biopharma industry to understand drug efficacy varies, improves the drug development process, and help identify key drugs and treatments for individual patients to improve patient outcomes. The company was founded in 2016 and is based in New York, New York.

Omada Health Logo
Omada Health

Omada Health is a digital behavioral medicine company. The company helps to protect patients from chronic conditions like heart disease and type 2 diabetes. It offers behavioral counseling by using insights about social networking, gaming, and behavioral science to motivate changes in lifestyle and deliver clinically-meaningful results. The company was founded in 2011 and is based in San Francisco, California.

ConcertAI Logo

ConcertAI specializes in integrated clinical RWD, AI solutions and outcomes science with a large RWD oncology dataset. ConcertAI develops a medical research tool suite that offers care-based oncology research and data analytics.

MDClone Logo

MDClone develops a system for ensuring patient confidentiality during the analysis of medical data. MDClone's system generates datasets combining real and fictitious patients, allowing researchers to conduct tests without exposing sensitive medical data and compromising personal details.

Standigm Logo

Standigm is an AI and systems biology-based startup that aims to expedite the drug discovery process. Standigm develops a computer modeling technology that learns medical and biological information and predicts the action mechanism of pharmaceutics in advance. This technology can improve the pharmaceutical development process by tailoring the application of previous know-hows, come up with possible combinations of pharmaceuticals, and optimize the selection of candidates and participants for clinical trials.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.